Ticker Details
Myriad Genetics, Inc. Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.
IPO Date:	October 6, 1995
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$554.41M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.54 | 2.12%
Avg Daily Range (30 D):	$0.17 | 3.64%
Avg Daily Range (90 D):	$0.15 | 3.29%

Institutional Daily Volume
Avg Daily Volume:	.9M
Avg Daily Volume (30 D):	1.29M
Avg Daily Volume (90 D):	1.32M

Trade Size
Avg Trade Size (Sh.):	127
Avg Trade Size (Sh.) (30 D):	95
Avg Trade Size (Sh.) (90 D):	95

Institutional Trades
Total Institutional Trades:	11,910
Avg Institutional Trade:	$1.85M
Avg Institutional Trade (30 D):	$1.65M
Avg Institutional Trade (90 D):	$1.77M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.46M
Avg Closing Trade (30 D):	$1.91M
Avg Closing Trade (90 D):	$1.91M
Avg Closing Volume:	117.18K

News

Jun 19, 2026 @ 9:39 AM Ovarian Cancer Diagnostics Market Size to Reach US... Source: Sns Insider

May 15, 2026 @ 3:00 PM Actress Jackie Tohn Got Results Nobody Wants But T... Source: Not Specified

May 14, 2026 @ 5:00 PM Global Cervical Cancer Diagnostics Market to Exhib... Source: Delveinsight

Feb 16, 2026 @ 9:15 PM Myriad Genetics to Release Fourth Quarter and Full... Source: Na

Feb 13, 2026 @ 3:00 PM Decoding Our DNA: The Human Impact Behind SNP Geno... Source: Towards Healthcare

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-4.29	$-.36	$-.07
Diluted EPS	$-4.29	$-.36	$-.07
Revenue	$829M	$200.4M	$209.8M
Gross Profit	$580M	$137.6M	$146.8M
Net Income / Loss	$-399.9M	$-34.1M	$-7.9M
Operating Income / Loss	$-388.9M	$-30.7M	$-5.7M
Cost of Revenue	$249M	$62.8M	$63M
Net Cash Flow	$25M	$-25.3M	$-3.5M
PE Ratio

Splits
Mar 26, 2009	2:1
Sep 12, 2000	2:1